Show simple item record

dc.contributor.authorChen, Wenjia
dc.contributor.authorTran, Trung N.
dc.contributor.authorSadatsafavi, Mohsen
dc.contributor.authorMurray, Ruth
dc.contributor.authorWong, Nigel Chong Boon
dc.contributor.authorAli, Nasloon
dc.contributor.authorAriti, Con
dc.contributor.authorBulathsinhala, Lakmini
dc.contributor.authorGil, Esther Garcia
dc.contributor.authorFitzGerald, J. Mark
dc.contributor.authorAlacqua, Marianna
dc.contributor.authorAl-Ahmad, Mona
dc.contributor.authorAltraja, Alan
dc.contributor.authorAl-Lehebi, Riyad
dc.contributor.authorBhutani, Mohit
dc.contributor.authorBjermer, Leif Hilding
dc.contributor.authorBjerrum, Anne-Sofie
dc.contributor.authorBourdin, Arnaud
dc.contributor.authorvon Bülow, Anna
dc.contributor.authorBusby, John
dc.contributor.authorCanonica, Giorgio Walter
dc.contributor.authorCarter, Victoria
dc.contributor.authorChristoff, George C.
dc.contributor.authorCosio, Borja G.
dc.contributor.authorCostello, Richard W.
dc.contributor.authorFonseca, João A.
dc.contributor.authorGibson, Peter G.
dc.contributor.authorYoo, Kwang-Ha
dc.contributor.authorHeaney, Liam G.
dc.contributor.authorHeffler, Enrico
dc.contributor.authorHew, Mark
dc.contributor.authorHilberg, Ole
dc.contributor.authorHoyte, Flavia
dc.contributor.authorIwanaga, Takashi
dc.contributor.authorJackson, David J.
dc.contributor.authorJones, Rupert C.
dc.contributor.authorKoh, Mariko Siyue
dc.contributor.authorKuna, Piotr
dc.contributor.authorLarenas-Linnemann, Désirée
dc.contributor.authorLehmann, Sverre
dc.contributor.authorLehtimäki, Lauri
dc.contributor.authorLyu, Juntao
dc.contributor.authorMahboub, Bassam
dc.contributor.authorMaspero, Jorge
dc.contributor.authorMenzies-Gow, Andrew N.
dc.contributor.authorNewell, Anthony
dc.contributor.authorSirena, Concetta
dc.contributor.authorPapadopoulos, Nikolaos G.
dc.contributor.authorPapaioannou, Andriana I.
dc.contributor.authorPerez-de-Llano, Luis
dc.contributor.authorPerng (Steve), Diahn-Warng
dc.contributor.authorPeters, Matthew
dc.contributor.authorPfeffer, Paul E.
dc.contributor.authorPorsbjerg, Celeste M.
dc.contributor.authorPopov, Todor A.
dc.contributor.authorRhee, Chin Kook
dc.contributor.authorSalvi, Sundeep
dc.contributor.authorTaillé, Camille
dc.contributor.authorTaube, Christian
dc.contributor.authorTorres-Duque, Carlos A.
dc.contributor.authorUlrik, Charlotte
dc.contributor.authorRa, Seung-Won
dc.contributor.authorWang, Eileen
dc.contributor.authorWechsler, Michael E.
dc.contributor.authorPrice, David B.
dc.date.accessioned2024-01-19T08:57:57Z
dc.date.available2024-01-19T08:57:57Z
dc.date.created2023-09-01T12:06:27Z
dc.date.issued2023
dc.identifier.issn2213-2198
dc.identifier.urihttps://hdl.handle.net/11250/3112697
dc.description.abstractBackground Effectiveness of biologics has neither been established in patients with high oral corticosteroid exposure (HOCS) nor been compared with effectiveness of continuing with HOCS alone. Objective To examine the effectiveness of initiating biologics in a large, real-world cohort of adult patients with severe asthma and HOCS. Methods This was a propensity score–matched, prospective cohort study using data from the International Severe Asthma Registry. Between January 2015 and February 2021, patients with severe asthma and HOCS (long-term OCSs for ≥1 year or ≥4 courses of rescue OCSs within a 12-month period) were identified. Biologic initiators were identified and, using propensity scores, matched 1:1 with noninitiators. The impact of biologic initiation on asthma outcomes was assessed using generalized linear models. Results We identified 996 matched pairs of patients. Both groups improved over the 12-month follow-up period, but improvement was greater for biologic initiators. Biologic initiation was associated with a 72.9% reduction in the average number of exacerbations per year versus noninitiators (0.64 vs 2.06; rate ratio, 0.27 [95% CI, 0.10-0.71]). Biologic initiators were 2.2 times more likely than noninitiators to take a daily long-term OCS dose of less than 5 mg (risk probability, 49.6% vs 22.5%; P = .002) and had a lower risk of asthma-related emergency department visits (relative risk, 0.35 [95% CI, 0.21-0.58]; rate ratio, 0.26 [0.14-0.48]) and hospitalizations (relative risk, 0.31 [95% CI, 0.18-0.52]; rate ratio, 0.25 [0.13-0.48]). Conclusions In a real-world setting, including patients with severe asthma and HOCS from 19 countries, and within an environment of clinical improvement, initiation of biologics was associated with further improvements across multiple asthma outcomes, including exacerbation rate, OCS exposure, and health care resource utilization.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleImpact of Inititing Biologics in Patients With Severe Asthma on Long-term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registryen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2023 The Author(s)en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1016/j.jaip.2023.05.044
dc.identifier.cristin2171634
dc.source.journalJournal of Allergy and Clinical Immunology: In Practiceen_US
dc.source.pagenumber2732-2747en_US
dc.identifier.citationJournal of Allergy and Clinical Immunology: In Practice. 2023, 11 (9), 2732-2747.en_US
dc.source.volume11en_US
dc.source.issue9en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal